Ranbaxy got USFDA nod with fudged data

An ex-employee of the company,Thakur,who was tasked with investigations of alleged malpractices in Ranbaxy,said: We started getting the files,and,lo and behold,we find that none of that exists in the first place 8230;. It means that weve gotten approvals from the FDA to sell drugs that were based on no data,or data that was fraudulent.

Pointing out how test results were allegedly manipulated,he said: When you find a blood sample rework for one patient copied 23 times because there are 24 patients needed to prove bioequivalence,thats not an error.

Ranbaxy spokespersons could not be reached for comments. Elaborating how the companys drug failed to provide relief,he said: The expectations is the drug is supposed to work as intended 8230; What we saw in this particular case is that trust was broken.

Recounting an incident where his son was prescribed a Ranbaxy antibiotic for a fever,Thakur said: He son kept getting worse,so we got another companys formulation and the fever went away.